Hemophilus-Influenzae Type-B (Hib) Polysaccharide Vaccine - Safety And Immunogenicity Of Prp And Prp-D Conjugate Vaccines In Children 16-24 Months

A multicenter study of the relative safety and immunogenicity of the purified heat-sized Hib polysaccharide (PRP) and conjugate (PRP-D) vaccines was conducted in 475 children 16-24 months of age. No serious reactions occurred in either group. Except for fewer febrile reactions in the PRP-D group (p<.05), other reactions were similar for both vaccines. Immune responses were measured by KIA (ug)ml and are summarized below: Although PRP is soon to be licensed for use in older children, PRP-D is at least as safe and significantly more immunogenic.